24 February 2025
24 February 2025
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed – for now.
Pfizer said resources will be directed to its other haemophilia gene therapy Hympavzi.
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for abuse.
MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind.
Bluebird has faced financial pressures over the last few years, leading to several restructuring efforts.
The drug replaces deficient bile acids, minimising abnormal cholesterol metabolite deposits.
Selarsdi has been approved by the US Food and Drug Administration in four presentations.
UroGen has initiated several research partnerships to investigate its RTGel technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
